Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Merck
AstraZeneca
Citi
Accenture
Chubb
Harvard Business School
Medtronic

Generated: April 22, 2018

DrugPatentWatch Database Preview

KENGREAL Drug Profile

« Back to Dashboard

Which patents cover Kengreal, and when can generic versions of Kengreal launch?

Kengreal is a drug marketed by Chiesi Usa Inc and is included in one NDA. There are seven patents protecting this drug.

This drug has ninety-two patent family members in forty-one countries.

The generic ingredient in KENGREAL is cangrelor. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the cangrelor profile page.
Summary for KENGREAL
Drug patent expirations by year for KENGREAL
Pharmacology for KENGREAL
Synonyms for KENGREAL
(dichloro((((((2R,3S,4R,5R)-3,4-dihydroxy-5-(6-((2-(methylthio)ethyl)amino)-2-((3,3,3-trifluoropropyl)thio)-9H-purin-9-yl)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosph
(Dichloromethylene)diphosphonic N-(2-(methylsulfanyl)ethyl)-2-((3,3,3-trifluoropropyl)sulfanyl-5'-adenylic monoanhydride
[dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
[dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]methyl]phosphonic acid
163706-06-7
5'-Adenylic acid, N-(2-(methylthio)ethyl)-2-((3,3,3-trifluoropropyl)thio)-, monoanhydride with (dichloromethylene)bis(phosphonic acid)
5'-Adenylicacid,N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)thio]-,anhydridewithP,P'-(dichloromethylene)bis[phosphonicacid](1:1)
5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]-N-[2-(methylsulfanyl)ethyl]-2-[(3,3,3-trifluoropropyl)sulfanyl]adenosine
6AQ1Y404U7
AC-28809
AK322508
AKOS027326862
AM85616
AMMD00024
AN-37839
AR-C 69931
AR-C-69931MX
AR-C69931MX
AR-C69931XX
ARL 69931MX
ARL69931
BDBM50118225
canegrelor
Cangrelor
Cangrelor (AR-C69931)
Cangrelor (USAN/INN)
Cangrelor [USAN:INN:BAN]
CHEBI:90841
CHEMBL334966
D03359
D09QBG
DB06441
DTXSID90167651
FT-0771866
GTPL1776
Kengreal (TN)
kengrexal
MFCD09837758
NU007008
oryl)methyl)phosphonic acid
SCHEMBL6113860
UNII-6AQ1Y404U7
ZINC85537017

US Patents and Regulatory Information for KENGREAL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Chiesi Usa Inc KENGREAL cangrelor POWDER;IV (INFUSION) 204958-001 Jun 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for KENGREAL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,320,754 Maintenance of platelet inhibition during antiplatelet therapy ➤ Sign Up
8,716,261 Maintenance of platelet inhibition during antiplatelet therapy ➤ Sign Up
8,871,736 Maintenance of platelet inhibition during antiplatelet therapy ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for KENGREAL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0060 France ➤ Sign Up PRODUCT NAME: CANGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,NOTAMMENT UN SEL TETRASODIQUE; REGISTRATION NO/DATE: EU/1/15/994/001 20150323
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Moodys
Medtronic
US Army
Fuji
Deloitte
Johnson and Johnson
McKesson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.